Initially developed for the treatment of type‐2 diabetes mellitus (T2DM), GLP‐1 and GIP/GLP‐1 RAs are presently licensed as anti‐obesity agents for obese or overweight adults with a body mass index (BMI) ≥ 30 kg/m2 or a BMI ≥ 27 kg/m2 with at least one cardiovascular risk factor (such as prediabetes, diabetes, hypertension, dyslipidemia, and elevated waist circumference) or obesity‐related comorbidity (including non‐alcoholic fatty liver disease and obstructive sleep apnea) [12]. This evidence concerns the gene GLP1R and prediabetes syndrome.